Empowering
people living with
rare immunologic diseases
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
Media
Our latest announcements
07/10/2024
03/10/2024
05/09/2024
23/08/2024
Our focus area
We aim to address unmet need in conditions where the IgG-driven immune response becomes harmful, or it interferes with the delivery of lifesaving and life altering therapies.
For Investors
Upcoming events
Interim Report for January-September 2024
Truist Securities BioPharma Symposium, New York
SEB Healthcare Seminar 2024, Stockholm
Media articles
Discover more
Partner with us
Our partnership model is focused in three key areas – drug discovery and development, commercialization and distribution / licensing.
PartnershipsJoin us
Ready for a new career? Check out our job opportunities.
A truly great place to work
For four years Hansa has been awarded the Great Place to Work designation by the independent institute Great Place to Work®, a global authority on workplace culture, employee experience and leadership behavior. In addition, Hansa was selected among the best workplaces in Sweden in 2023.
Job opportunitiesLife on tour with chronic kidney disease
“I had always played the guitar and wrote songs but never really did anything with it. Nothing was going to hold me back now! No more excuses… there wasn’t time!”
Suspended time: a journey from diagnosis to transplant
"Dialysis may sound simple, but it isn’t, and over the course of his treatment Ron underwent several different kinds, all of which made him feel awful."
Taking care of a transplanted kidney through physical and mental health
“And people say to me: I never would have guessed that you had a kidney transplant… when I hear those words, they keep me motivated, and keep me going.”
Working in an epicentre of pioneering innovation
“The key to our collective success at Hansa Biopharma goes far beyond our scientific breakthroughs, as it stems from the amazing team spirit we have built.”
